RxDoctor Payments Data

Frances Velez Lago, MD

Neurology · Guaynabo, PRNPI 1902002777

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,605 of the $15,346 with a category attached, or 75.6%. AbbVie accounts for 71.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $5,369 and has fallen 64.4% since, to $1,909 in 2025.

$15,346in general payments, 2019–2025

Across 82 payments — averaging $187.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Acorda Therapeutics, Inc$1K
  • Abbott$873
  • Amneal Pharmaceuticals LLC$371
  • Teva Pharmaceuticals USA, Inc.$349
  • Acadia Pharmaceuticals Inc$213
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$11,60576%
  • Speaking & faculty fees$390%
  • Travel & lodging$7315%
  • Food & beverage$2,96919%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,346 in reported general payments places this provider in the 85th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,945
Medicare patients
29
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate54$270,912
AustedoDeutetrabenazine24$173,650
RytaryCarbidopa/Levodopa82$55,783
Carbidopa-LevodopaCarbidopa/Levodopa265$12,368
Rasagiline Mesylate71$10,920
RivastigmineRivastigmine Tartrate150$7,787
Donepezil Hcl387$6,210
Rivastigmine43$5,624
Memantine Hcl207$5,384
Carbidopa-Levodopa ErCarbidopa/Levodopa60$3,820
Selegiline Hcl35$3,110
Primidone69$2,951
Galantamine ErGalantamine Hbr33$2,927
Memantine Hcl ErMemantine Hcl32$2,383
AmantadineAmantadine Hcl42$2,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$213$270,91254 claims
Teva Pharmaceuticals USA, Inc.Austedo$349$173,65024 claims
Amneal Pharmaceuticals LLCRytary$371$55,78382 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 neurology providers in Puerto Rico.

Other neurology in Guaynabo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →